A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

By R. Shi, Chao Shan, Xiaomin Duan, Zhihai Chen, Peipei Liu, Jinwen Song, Tao Song, Xiaoshan Bi, Chao Han, Lian-ao Wu and 15 more. Nature, 2020

1,274 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection (2020, background): “recently been described (54, 55), although their in vitro neutralizing concentrations are at least 10-fold higher.”
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding (2020, neutral): “The RBD is the dominant target of neutralizing antibodies (Cao et al., 2020; Ju et al., 2020; Pinto et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wu et al., 2020b; Zost et al., 2020), and so any antigenic drift will be constrained by its mutational tolerance.”
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding (2020, positive): “In addition, the RBD is the target of the most potent anti-SARS-CoV-2 neutralizing antibodies identified to date (Cao et al., 2020; Ju et al., 2020; Pinto et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wu et al., 2020; Zost et al., 2020), and several promising vaccine can”